Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis

By sjmartinez • June 23, 2024

Armstrong AW, Park SH, Patel V, Nicolas P, Wang WJ, Colombo MJ, Chirikov V. Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis. Dermatol Ther (Heidelb). 2024 Jun 22. doi: 10.1007/s13555-024-01201-4. Epub ahead of print. PMID: 38907877.

Tags: apremilast, cumulative clinical benefit, Dermatology, deucravacitinib, Oral treatments, psoriasis, Publications, Small molecules

Inhibition of pyruvate oxidation diminishes melanoma progression

Seyran B, Avila I, Galvan C, Robles G, Murphy C, Christofk H, Lowry WE. Inhibition of pyruvate oxidation diminishes melanoma progression. J Invest Dermatol. 2024[...]

Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement

Akiska YM, Mirmirani P, Roseborough I, Mathes E, Bhutani T, Ambrosy A, Aguh C, Bergfeld W, Callender VD, Castelo-Soccio L, Cotsarelis G, Craiglow BG, Desai[...]

Mart-1 During Mohs Micrographic Surgery for Melanoma Excision Results in Decreased Stage Number and Decreased Frequency of Secondary Pathologic Consultation

Zhang R, Yueh K, Anderson M, Bennett RG. Mart-1 During Mohs Micrographic Surgery for Melanoma Excision Results in Decreased Stage Number and Decreased Frequency of[...]